Epigallocatechin gallate attenuates experimental non-alcoholic steatohepatitis induced by high fat diet

• Published in: Journal of gastroenterology and hepatology 2008-08, Vol.23 (8pt2), p.e465-e470
• Main Authors: Kuzu, Nalan, Bahcecioglu, Ibrahim Halil, Dagli, Adile Ferda, Ozercan, Ibrahim Hanifi, Ustündag, Bilal, Sahin, Kazim
• Format: Article
• Language: English
• Subjects: Animals; Antioxidants - therapeutic use; Catechin - analogs & derivatives; Catechin - therapeutic use; Diet - adverse effects; Dietary Fats - adverse effects; Disease Models, Animal; epigallocatechin gallate; Fatty Liver - etiology; Fatty Liver - pathology; Fatty Liver - prevention & control; high fat diet; Liver - pathology; Male; non-alcoholic fatty liver; Rats; Rats, Sprague-Dawley; steatohepatitis
• ISSN: 0815-9319; 1440-1746
• DOI: 10.1111/j.1440-1746.2007.05052.x

Background and Aim:  In the present study, we examined the preventive role of epigallocatechin gallate (EGCG) in an experimental non‐alcoholic steatohepatitis model induced by a high fat diet. Methods:  The study included 21 male Sprague‐Dawley rats, which were equally divided into three groups. The first group was fed on a standard rat diet, the second group on a high fat diet (HFD), and the third group on a HFD + EGCG. The study concluded after 6 weeks. Histopathological examination was performed. Plasma and tissue MDA levels, glucose, insulin, alanine aminotransferase (ALT), aspartate aminotransferase, gamma glutamyltransferase, alkaline phosphatase, triglyceride, and cholesterol levels were studied. Insulin resistance was calculated by the homeostasis model of insulin resistance method. Results:  Steatosis, inflammation, ballooning degeneration, and necrosis increased significantly in the HFD group, compared to the control group (P